表紙:橋本病の世界市場:予測(2022年~2028年)
市場調査レポート
商品コード
1123246

橋本病の世界市場:予測(2022年~2028年)

Global Hashimoto's Thyroiditis Market Research and Forecast 2022-2028

出版日: | 発行: Orion Market Research | ページ情報: 英文 125 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
橋本病の世界市場:予測(2022年~2028年)
出版日: 2022年08月01日
発行: Orion Market Research
ページ情報: 英文 125 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の橋本病の市場規模は、2022年から2028年の予測期間中に顕著なCAGRで成長すると予測されています。市場の成長を後押しする主な要因には、自己免疫性甲状腺疾患の増加、ヨウ素の欠乏、疾患に関する意識の高まりなどが挙げられます。一方で、治療薬に対する食品医薬品局の厳しい規制などが、市場の成長を抑制する可能性があります。

当レポートでは、世界の橋本病市場を調査しており、市場の概要、市場の促進要因・抑制要因の分析、診断・治療・流通チャネル・地域別の分析、競合情勢、さらに主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 競合ダッシュボード
  • 主要戦略分析
  • 主要企業分析
    • AbbVie Inc.
    • Pfizer Inc.
    • Merck KGaA
    • IBSAInstitutBiochimique SA

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の橋本病市場:診断別
    • 甲状腺刺激ホルモン検査
    • チロキシン検査
    • 抗甲状腺抗体検査
  • 世界の橋本病市場:治療別
    • レボチロキシン
    • トリヨードチロニン
    • 乾燥甲状腺エキス
    • その他(リオチロニン、プロピルチオウラシル)
  • 世界の橋本病市場:流通チャネル別
    • 病院薬局
    • 小売薬局

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第7章 企業プロファイル

  • AcellaPharmaceuticals, LLC
  • Allergan plc
  • Bio-Rad Laboratories, Inc.
  • General Electric Co.
  • Intas Pharmaceuticals Ltd.
  • Jerome Stevens Pharmaceuticals, Inc.
  • Lannett Company, Inc.
  • Lupin Ltd.
  • Mylan NV
  • Novartis AG
  • RLC Labs
  • Taj Pharmaceuticals Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL HASHIMOTO'S THYROIDITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL THYROID-STIMULATING HORMONE TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL THYROXINE TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL ANTITHYROID ANTIBODY TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

5. GLOBAL HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,

  • 6. GLOBAL LEVOTHYROXINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL TRIIODOTHYRONINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 10. GLOBAL HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 12. NORTH AMERICAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 13. NORTH AMERICAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 14. NORTH AMERICAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN HASHIMOTO'S THYROIDITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 16. EUROPEAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. EUROPEAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 18. EUROPEAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 19. EUROPEAN HASHIMOTO'S THYROIDITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 20. ASIA-PACIFIC HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 21. ASIA-PACIFIC HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 22. ASIA-PACIFIC HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC HASHIMOTO'S THYROIDITIS TREATMENT MARKET RESEARCH AND ANALYSIS BYDISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 24. REST OF THE WORLD HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 25. REST OF THE WORLD HASHIMOTO'S TREATMENT THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 26. REST OF THE WORLD HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 2. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 3. GLOBAL HASHIMOTO'S THYROIDITIS TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 4. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL THYROID-STIMULATING HORMONE TEST MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 6. GLOBAL THYROXINE TEST MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 7. GLOBAL ANTITHYROID ANTIBODY TEST MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL LEVOTHYROXINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL TRIIODOTHYRONINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL DESICCATED THYROID EXTRACT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL HOSPITAL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL RETAIL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. US HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 14. CANADA HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 15. UK HASHIMOTO'S THYROIDITIS AND THYROXINE TEST MARKET SIZE, 2020-2027($ MILLION)
  • 16. FRANCE HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 17. GERMANY HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 18. ITALY HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 19. SPAIN HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 20. REST OF EUROPE HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 21. INDIA HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 22. CHINA HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 23. JAPAN HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 24. SOUTH KOREA HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 25. REST OF ASIA-PACIFIC HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 26. REST OF THE WORLD HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
目次
Product Code: OMR2018404

Global Hashimoto's Thyroiditis Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Thyroid-Stimulating Hormone Test, Thyroxine Test, Antithyroid Antibody Test), By Treatment (Levothyroxine, Triiodothyronine, Desiccated Thyroid Extract and other), Distribution Channel (Hospital Pharmacies, and Retail Pharmacies) Forecast Period 2021-2027

Global Hashimoto's thyroiditis market is anticipated to grow at a considerable CAGR during the forecast period. Hashimoto's thyroiditis is a condition in which the immune system attacks the thyroid and gradually leads to hyperthyroidism. Production of immune cells and autoantibodies by the body's immune system are characteristics of Hashimoto's thyroiditis, which can damage thyroid cells and compromise their ability to make thyroid hormones. There are various treatment methods for such diseases by using replacement agents such as levothyroxine, triiodothyronine, or desiccated thyroid extract. The increasing autoimmune thyroid diseases and deficiency of iodine are responsible for the growth in the demand for Hashimoto's Thyroiditis treatment. Furthermore, there are various national health programs related to thyroid disease that raise awareness regarding such diseases that further fuel the growth of Hashimoto's thyroiditis market.

However, there are stringent regulations of food and drug administration regarding medication of Hashimoto's Thyroiditis which acts as an obstacle for the market. Although, further research and development for Hashimoto's diseases and the cost-effectiveness of the treatment will turn out to be a huge opportunity for the adoption of Hashimoto's thyroiditis treatment.

Segmental Outlook

The global Hashimoto's thyroiditis market is segmented based on diagnosis, treatment, and distribution channels. In diagnosis, the market is segmented into Thyroid-stimulating hormone tests, thyroxine tests, antithyroid antibody tests. Moreover, based on treatment, the market is segmented into levothyroxine, triiodothyronine, desiccated thyroid extract, and others. By distribution channel, the treatment market is segmented into hospital pharmacies and retail pharmacies.

Levothyroxine is a major treatment and is considered to dominate the market

Levothyroxine is the first line of treatment for Hashimoto's thyroiditis and will be the dominating segment during the forecast period. Levothyroxine is a hormone medicine treatment for the underactive thyroid gland, the following medicine helps in replacing the missing thyroid hormone. The drug is available in the brand name such as Synthroid, Levoxyl, and Unithroid which are available as oral tablets, oral capsules, or injectable solutions. The medicine is a prescription drug and is used in form of combination therapy. Levothyroxine might be taken life-long while treating hypothyroidism unless the disease becomes transient.

Regional Outlooks

The global Hashimoto's thyroiditis market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to have a significant market during the forecast period attributed to factors such as the large presence of healthcare facilities in the region, high awareness among the people about the diseases, strategic collaborations between the pharmaceutical companies and government organizations. As per ClinCalc LLC, Levothyroxine was the second most prescribed drug in the US in 2018, a rank higher than a year ago. Around 105 million prescriptions of Levothyroxine were registered in 2018 in the US. AbbVie Inc. is a major manufacturer of Levothyroxine as Synthroid. The company generated a revenue of $770-$780 million each year in the period 2018-2020 from the sale of Levothyroxine as Synthroid in the US.

Asia-Pacific will have significant growth in the global Hashimoto's Thyroiditis Market

Asia Pacific is expected to register significant growth in Hashimoto's Thyroiditis market. The growth is attributed to rising healthcare infrastructure in emerging economies including China, India, and ASEAN countries, along with that rising insurance payer, development, and expansion of public and private healthcare sectors. Further one of the major reasons for the growth of the market in this region is huge investment is done by global companies in local companies of the region due to the presence of raw materials and labor at cheaper cost. The availability of generics in the region is also a major reason for the rise of the market.

Market Players Outlook

The key players of Hashimoto's thyroiditis market include AbbVie Inc., Pfizer Inc., Merck KGaA, IBSA Institut Biochimique SA, among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Lannett Company, Inc., launched Cediprof, Inc.'s FDA-approved Levothyroxine Sodium Tablets USP, under the companies interim exclusive supply and distribution agreement in the US.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Penicillin and Streptomycin market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Competitive Dashboard
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AbbVie Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Pfizer Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Merck KGaA
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. IBSAInstitutBiochimique SA
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Hashimoto's Thyroiditis Diagnosis and Treatment Market by Diagnosis
    • 5.1.1. Thyroid-Stimulating Hormone Test
    • 5.1.2. Thyroxine Test
    • 5.1.3. Antithyroid Antibody Test
  • 5.2. Global Hashimoto's Thyroiditis Diagnosis and Treatment Market by Treatment
    • 5.2.1. Levothyroxine
    • 5.2.2. Triiodothyronine
    • 5.2.3. Desiccated Thyroid Extract
    • 5.2.4. Other (Liothyronine, Propylthiouracil)
  • 5.3. Global Hashimoto's Thyroiditis Treatment Market by Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AcellaPharmaceuticals, LLC
  • 7.2. Allergan plc
  • 7.3. Bio-Rad Laboratories, Inc.
  • 7.4. General Electric Co.
  • 7.5. Intas Pharmaceuticals Ltd.
  • 7.6. Jerome Stevens Pharmaceuticals, Inc.
  • 7.7. Lannett Company, Inc.
  • 7.8. Lupin Ltd.
  • 7.9. Mylan NV
  • 7.10. Novartis AG
  • 7.11. RLC Labs
  • 7.12. Taj Pharmaceuticals Ltd.